PAncreatic Adenocarcinoma in Hospital
APACH
1 other identifier
observational
1,204
2 countries
66
Brief Summary
Few data are currently available in the literature on pancreatic adenocarcinoma in France. About 8,000 new cases each year in France. The 5-year survival for all stages combined is \<5%. This is the only digestive cancer in which mortality / incidence ratio is 98%. Epidemiological characteristics at diagnosis, the impact on the survival of recent advances related to surgery, adjuvant chemotherapy and new standard forms of adjuvant chemotherapy (FOLFIRINOX) are mispriced in real life. The development of new drugs and the development of Phase II and III require a better understanding of the state of this disease in the country. The main objective is to describe the characteristics of the pancreatic adenocarcinoma at diagnosis in France and make an inventory of diagnostic practices and support.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2013
Longer than P75 for all trials
66 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 18, 2013
CompletedFirst Submitted
Initial submission to the registry
November 6, 2013
CompletedFirst Posted
Study publicly available on registry
November 21, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 4, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2020
CompletedMarch 14, 2022
March 1, 2022
2.1 years
November 6, 2013
March 11, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Survival
patient death (following during 5 year)
Study Arms (1)
Pancreatic Adenocarcinoma
Eligibility Criteria
patient in hepatogastroenterology in general hospital
You may qualify if:
- Living in France
- Pancreatic adenocarcinoma histologically or cytologically proven
- primary diagnosis
- Agreed to participate
You may not qualify if:
- Suspected pancreatic adenocarcinoma histologically or cytologically unproven
- Refused to participate
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (66)
CH de Jolimont
Jolimont, Belgium
CH Gabriel Martin
Saint-Paul, La Réunion, 97866, France
CHIAP
Aix-en-Provence, 13616, France
CH Angoulême
Angoulême, France
CH d'Aubenas
Aubenas, 07200, France
CH Auch
Auch, 32008, France
CH Robert Ballanger
Aulnay-sous-Bois, France
CH Avignon
Avignon, France
CH Bagnols sur Ceze
Bagnols-sur-Cèze, France
CH Bayeux
Bayeux, 14400, France
CH Béziers
Béziers, 34500, France
CH Blois
Blois, 41016, France
CH Bourg en Bresse
Bourg-en-Bresse, France
CH de Bourges
Bourges, 18000, France
CH Nord Deux Sèvres
Bressuire, France
CH Saint Camille
Bry-sur-Marne, France
HPA Castres Mazamet
Castres, 81108, France
CH Chambery
Chambéry, France
CH Chartres
Chartres, 28630, France
CH Chalons en champagne
Châlons-en-Champagne, France
CH Haut Anjou
Château-Gontier, France
CH Châteauroux
Châteauroux, 36000, France
Ch Cholet
Cholet, France
CH Compiègne Noyon
Compiègne, France
CH sud francilien
Corbeil-Essonnes, France
CH de Creil
Creil, 60109, France
CHI Créteil
Créteil, 94000, France
CH Dourdan
Dourdan, France
CH Draguignan
Draguignan, France
CH Dreux
Dreux, 28100, France
CH Simone Veil
Eaubonne, 95600, France
CH Forcilles
Férolles, France
Chicas
Gap, France
CH Gonesse
Gonesse, 95500, France
Centre hospitalier départemental Vendée
La Roche-sur-Yon, 85925, France
Centre Hospitalier de Lagny
Lagny-sur-Marne, 77400, France
CH du Mans
Le Mans, France
Lens
Lens, France
Centre Hospitalier Côté de lumière
Les Sables-d'Olonne, 85100, France
Hôpital des chanaux
Mâcon, France
Centre Hospitalier de Meaux
Meaux, 77100, France
CH Melun
Melun, France
CHR de Mercy-Metz
Metz, France
CHAM
Montargis, 45207, France
CH Montauban
Montauban, France
Centre Hospitalier Montelimar
Montélimar, 26200, France
CH Montfermeil
Montfermeil, France
CH Niort
Niort, France
CHG Oloron
Oloron-Sainte-Marie, France
CHR Orléans
Orléans, 45000, France
CH François Mitterand
Pau, France
Centre Hospitalier de Perpignan
Perpignan, 66046, France
CHI Poissy Saint Germain
Poissy, 78600, France
CH Pontoise
Pontoise, France
CH de la région d'Annecy
Pringy, 74374, France
CH Quimper
Quimper, 29107, France
CH Roubaix
Roubaix, France
Centre hospitalier Yves Le Foll
Saint-Brieuc, 22200, France
CH de la Fontaine
Saint-Denis, France
CH Saint Quentin
Saint-Quentin, France
Centre Hospitalier de Bigorre
Tarbes, 65013, France
CH Sainte Musse
Toulon, France
CH Tourcoing
Tourcoing, France
CH Valenciennes
Valenciennes, France
CHBA de Vannes
Vannes, 56017, France
CHIV Villeneuve Saint-Georges
Villeneuve-Saint-Georges, 94190, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Roger FAROUX, PH
Centre hospitalier départemental Vendée
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 6, 2013
First Posted
November 21, 2013
Study Start
October 18, 2013
Primary Completion
December 4, 2015
Study Completion
December 1, 2020
Last Updated
March 14, 2022
Record last verified: 2022-03